Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

An innovative and highly drug-tolerant approach for detecting neutralizing antibodies directed to therapeutic antibodies.

Sloan JH, Conway RG, Pottanat TG, Troutt JS, Higgs RE, Konrad RJ, Qian YW.

Bioanalysis. 2016 Oct;8(20):2157-68. doi: 10.4155/bio-2016-0161. Epub 2016 Sep 5.

PMID:
27593891
2.

A dual-monoclonal, sandwich immunoassay specific for glucagon like peptide-19-36/7 (GLP-19-36/7).

Osborne RI, Ming W, Troutt JS, Siegel RW, Konrad RJ.

Clin Biochem. 2016 Aug;49(12):897-902. doi: 10.1016/j.clinbiochem.2016.03.014. Epub 2016 May 18.

PMID:
27208557
3.

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.

Leander K, Mälarstig A, Van't Hooft FM, Hyde C, Hellénius ML, Troutt JS, Konrad RJ, Öhrvik J, Hamsten A, de Faire U.

Circulation. 2016 Mar 29;133(13):1230-9. doi: 10.1161/CIRCULATIONAHA.115.018531. Epub 2016 Feb 19.

PMID:
26896437
4.

Affinity capture elution bridging assay: A novel immunoassay format for detection of anti-therapeutic protein antibodies.

Chen YQ, Pottanat TG, Carter QL, Troutt JS, Konrad RJ, Sloan JH.

J Immunol Methods. 2016 Apr;431:45-51. doi: 10.1016/j.jim.2016.02.008. Epub 2016 Feb 10.

PMID:
26874304
5.

Novel sandwich immunoassays for the measurement of total and active FGF21.

Umberger TS, Sloan JH, Chen J, Cheng C, Siegel RW, Qian Y, Troutt JS, Konrad RJ.

Bioanalysis. 2014;6(24):3283-93. doi: 10.4155/bio.14.241.

PMID:
25534786
6.

Isolation and characterization of the circulating truncated form of PCSK9.

Han B, Eacho PI, Knierman MD, Troutt JS, Konrad RJ, Yu X, Schroeder KM.

J Lipid Res. 2014 Jul;55(7):1505-14. doi: 10.1194/jlr.M049346. Epub 2014 Apr 28.

8.

Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein ε2.

Brouwers MC, van Greevenbroek MM, Konrad RJ, Troutt JS, Schaper NC, Stehouwer CD.

Clin Sci (Lond). 2014 May;126(9):679-84. doi: 10.1042/CS20130556.

PMID:
24308640
9.
10.

Serum hepcidin levels are associated with obesity but not liver disease.

Vuppalanchi R, Troutt JS, Konrad RJ, Ghabril M, Saxena R, Bell LN, Kowdley KV, Chalasani N.

Obesity (Silver Spring). 2014 Mar;22(3):836-41. doi: 10.1002/oby.20403. Epub 2013 Dec 17.

11.

Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.

Brouwers MC, Konrad RJ, van Himbergen TM, Isaacs A, Otokozawa S, Troutt JS, Schaefer EJ, van Greevenbroek MM, Stalenhoef AF, de Graaf J.

Nutr Metab Cardiovasc Dis. 2013 Nov;23(11):1115-21. doi: 10.1016/j.numecd.2012.11.008. Epub 2013 Jan 18.

PMID:
23333725
12.

Determination of cathepsin S abundance and activity in human plasma and implications for clinical investigation.

Cox JM, Troutt JS, Knierman MD, Siegel RW, Qian YW, Ackermann BL, Konrad RJ.

Anal Biochem. 2012 Nov 15;430(2):130-7. doi: 10.1016/j.ab.2012.08.011. Epub 2012 Aug 23.

PMID:
22922382
13.

Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration.

Troutt JS, Rudling M, Persson L, Ståhle L, Angelin B, Butterfield AM, Schade AE, Cao G, Konrad RJ.

Clin Chem. 2012 Aug;58(8):1225-32. doi: 10.1373/clinchem.2012.186866. Epub 2012 Jun 7.

14.

Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels.

Chernogubova E, Strawbridge R, Mahdessian H, Mälarstig A, Krapivner S, Gigante B, Hellénius ML, de Faire U, Franco-Cereceda A, Syvänen AC, Troutt JS, Konrad RJ, Eriksson P, Hamsten A, van 't Hooft FM.

Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1526-34. doi: 10.1161/ATVBAHA.111.240549. Epub 2012 Mar 29.

PMID:
22460556
15.

Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia.

Brouwers MC, van Greevenbroek MM, Troutt JS, Bonner Freeman A, Lu A, Schaper NC, Konrad RJ, Stehouwer CD.

Clin Sci (Lond). 2011 Nov;121(9):397-403. doi: 10.1042/CS20110129.

PMID:
21539517
16.

Dual-monoclonal, sandwich immunoassay specific for glucose-dependent insulinotropic peptide1-42, the active form of the incretin hormone.

Troutt JS, Siegel RW, Chen J, Sloan JH, Deeg MA, Cao G, Konrad RJ.

Clin Chem. 2011 Jun;57(6):849-55. doi: 10.1373/clinchem.2010.159954. Epub 2011 Apr 22.

17.

Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.

Brouwers MC, Troutt JS, van Greevenbroek MM, Ferreira I, Feskens EJ, van der Kallen CJ, Schaper NC, Schalkwijk CG, Konrad RJ, Stehouwer CD.

Atherosclerosis. 2011 Jul;217(1):263-7. doi: 10.1016/j.atherosclerosis.2011.03.023. Epub 2011 Mar 25.

18.

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.

Konrad RJ, Troutt JS, Cao G.

Lipids Health Dis. 2011 Feb 28;10:38. doi: 10.1186/1476-511X-10-38.

19.

Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population.

Cui Q, Ju X, Yang T, Zhang M, Tang W, Chen Q, Hu Y, Haas JV, Troutt JS, Pickard RT, Darling R, Konrad RJ, Zhou H, Cao G.

Atherosclerosis. 2010 Dec;213(2):632-6. doi: 10.1016/j.atherosclerosis.2010.09.027. Epub 2010 Oct 30.

PMID:
21040917
20.

Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans.

Persson L, Cao G, Ståhle L, Sjöberg BG, Troutt JS, Konrad RJ, Gälman C, Wallén H, Eriksson M, Hafström I, Lind S, Dahlin M, Amark P, Angelin B, Rudling M.

Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2666-72. doi: 10.1161/ATVBAHA.110.214130. Epub 2010 Sep 30.

PMID:
20884874
21.

Development of a novel sandwich ELISA for measuring cell lysate ABCA1 protein levels.

Troutt JS, Alborn WE, Bellinger MA, Cox KL, Ehsani ME, Wang X, Qian YW, Sloan JH, Willey MB, Cao G, Konrad RJ.

Lipids. 2010 Aug;45(8):757-64. doi: 10.1007/s11745-010-3448-6. Epub 2010 Jul 17.

PMID:
20640528
22.

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol.

Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ.

J Lipid Res. 2010 Sep;51(9):2714-21. doi: 10.1194/jlr.M008144. Epub 2010 Jun 5.

23.

Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9.

Humphries SE, Neely RD, Whittall RA, Troutt JS, Konrad RJ, Scartezini M, Li KW, Cooper JA, Acharya J, Neil A.

Clin Chem. 2009 Dec;55(12):2153-61. doi: 10.1373/clinchem.2009.129759. Epub 2009 Oct 1.

24.

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.

Troutt JS, Alborn WE, Cao G, Konrad RJ.

J Lipid Res. 2010 Feb;51(2):345-51. doi: 10.1194/jlr.M000620. Epub 2009 Sep 8.

25.

An apolipoprotein A-I mimetic dose-dependently increases the formation of prebeta1 HDL in human plasma.

Troutt JS, Alborn WE, Mosior MK, Dai J, Murphy AT, Beyer TP, Zhang Y, Cao G, Konrad RJ.

J Lipid Res. 2008 Mar;49(3):581-7. Epub 2007 Dec 3.

26.

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ.

J Lipid Res. 2008 Feb;49(2):394-8. Epub 2007 Nov 21.

Supplemental Content

Loading ...
Support Center